A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study

被引:30
作者
Kadi, Adnan A. [1 ]
Abdelhameed, Ali S. [1 ]
Darwish, Hany W. [1 ,2 ]
Attwa, Mohamed W. [1 ]
Al-Shakliah, Nasser S. [1 ]
机构
[1] King Saud Univ, Dept Pharmaceut Chem, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia
[2] Cairo Univ, Dept Analyt Chem, Fac Pharm, Kasr El Aini St, Cairo 11562, Egypt
关键词
afatinib; LC-MS; MS; human plasma; metabolic stability study; PHASE-I; DOSE-ESCALATION; OPEN-LABEL; BIBW; 2992; PHARMACOKINETICS; INHIBITOR; SCHEDULE; KINASE; EGFR;
D O I
10.1002/bmc.3674
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Afatinib (AFT) is a new tyrosine kinase inhibitor approved for the treatment of nonsmall cell lung cancer. In the present study, a simple, specific, rapid and sensitive liquid chromatography tandem mass-spectrometric method for the quantification of AFT in human plasma, was developed and validated. Chromatographic separation of the analytes was accomplished on a reversed-phase Luna((R))-PFP 100 angstrom column (50x2.0mm; 3.0m) maintained at ambient temperature. Isocratic elution was carried out using acetonitrile-water (40:60, v/v) containing 10mm ammonium formate buffer (pH4.5) adjusted with formic acid at a flow rate of 0.4mLmin(-1). The analytes were monitored by electrospray ionization in positive ion multiple reaction monitoring mode. The method yields a linear calibration plot (r(2)=0.9997) from a quantification range of 0.5-500ngmL(-1) with the lower limit of quantification and lower limit of detection of 1.29 and 0.42ngmL(-1), respectively. The intra- and inter-day precision and accuracy were estimated and found to be in the ranges of 1.53-4.11% for precision and -2.80-0.38% for accuracy. Finally, quantification of afatinib in a metabolic stability study in rat liver microsomes was achieved through the proposed method. Copyright (c) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1248 / 1255
页数:8
相关论文
共 19 条
[1]  
[Anonymous], 2013, AF
[2]  
BILLINGS RE, 1983, J PHARMACOL EXP THER, V225, P630
[3]   A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [J].
Eskens, Falm ;
Mom, C. H. ;
Planting, A. S. T. ;
Gietema, J. A. ;
Amelsberg, A. ;
Huisman, H. ;
van Doorn, L. ;
Burger, H. ;
Stopfer, P. ;
Verweij, J. ;
de Vries, Ege .
BRITISH JOURNAL OF CANCER, 2008, 98 (01) :80-85
[4]   High-Throughput Microsomal Stability Assay for Screening New Chemical Entities in Drug Discovery [J].
Fonsi, Massimiliano ;
Orsale, Maria V. ;
Mionteagudo, Edith .
JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (09) :862-869
[5]   Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection [J].
Fouad, Marwa ;
Helvenstein, Maxime ;
Blankert, Bertrand .
JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY, 2015, 2015
[6]   A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors [J].
Gordon, Michael S. ;
Mendelson, David S. ;
Gross, Mitchell ;
Uttenreuther-Fischer, Martina ;
Ould-Kaci, Mahmoud ;
Zhao, Yihua ;
Stopfer, Peter ;
Agus, David B. .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :409-416
[7]  
International Conference on Harmonisation, 2005, Q2 R1 VAL AN PROC TE
[8]  
International Conference on Harmonization, 2000, GUID IND Q2B VAL AN
[9]   Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy. [J].
Kristeleit, H. ;
Puglisi, M. ;
Middleton, G. W. ;
Propper, D. ;
Kelleher, M. T. ;
Trani, L. ;
Denholm, K. A. ;
Wallenstein, G. ;
Stopfer, P. ;
Buschke, S. ;
Uttenreuther-Fischer, M. M. ;
Bent, E. ;
O'Brien, D. ;
Spicer, J. F. ;
Molife, L. R. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[10]   A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors [J].
Marshall, John ;
Hwang, Jimmy ;
Eskens, Ferry A. L. M. ;
Burger, Herman ;
Malik, Shakun ;
Uttenreuther-Fischer, Martina ;
Stopfer, Peter ;
Ould-Kaci, Mahmoud ;
Cohen, Roger B. ;
Lewis, Nancy L. .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :399-408